Tao Zhu¹, Taofeng Wei¹, Mingdong Yang¹, Junjun Xu¹, Huifang Jiang¹, Wei He¹, Juyan Zheng^2,*, Haibin Dai^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070180 - 30 December 2025

Abstract Background: Aberrant expression of transcription factors (TFs) is a key mechanism mediating tumor immune escape and therapeutic resistance. The involvement of E26 transformation-specific (ETS) family of TFs in immune regulation is not fully understood. The study aimed to elucidate the function of E-twenty-six variant 4 (ETV4) in tumor immune evasion and its potential as a predictive biomarker for immunotherapy in melanoma. Methods: The expression patterns of ETS family TFs were analyzed in melanoma and hepatocellular carcinoma (HCC). Single-cell RNA sequencing (scRNA-seq) was used to dissect the cellular expression and function of ETV4 in the tumor… More >

Xingchao Song^1,#, Qiuyu Song^2,#, Xiao Ma¹, Anzhi Xu¹, Chunyan Tian^1,*

Oncology Research, Vol.33, No.11, pp. 3583-3603, 2025, DOI:10.32604/or.2025.067638 - 22 October 2025

Abstract Background: Motif interacting with ubiquitin-containing novel DUB family-1 (MINDY1) could enhance the stability of programmed death-ligand 1 (PD-L1). The study aimed to investigate whether MINDY1 regulates the immune escape of hepatocellular carcinoma (HCC) mediated by PD-L1. Methods: MINDY1 and PD-L1 levels were detected through Western blot. The link between MINDY1 and PD-L1 was validated using the co-immunoprecipitation assay. The malignant biology of HCC cells was assessed through Cell Counting Kit-8, Carboxyfluorescein Succinimidyl Ester staining, transwell, and wound healing assay. CD8⁺ T cells were isolated and then co-cultured with HCC cells. Enzyme-linked immunosorbent Assay kits detected CD8⁺… More > Graphic Abstract

CHENG CHENG^1,2,3, CHAO SHI^1,2, SHANG WU^1,2, WEIXING WU³, JINGPING LI^1,2, SINUO GAO^1,2, MENG HAN³, YIMIN WANG³, XIANGMEI ZHANG^2,4,*, YUNJIANG LIU^1,2,*

Oncology Research, Vol.33, No.7, pp. 1633-1648, 2025, DOI:10.32604/or.2025.061637 - 26 June 2025

Abstract Objectives: While programmed cell death 1 (PD-1) inhibitors have improved cancer treatment, the function and mechanisms of programmed cell death ligand 1 (PD-L1), particularly when expressed by cancer cells, remain unclear. This study aims to explore the role of PD-L1 within breast cancer cells and identify key targets for future immunotherapy. Methods: RNA-seq was performed on breast cancer cells with silenced PD-L1 to screen for differentially expressed genes, followed by bioinformatics analysis. Clinical specimens from breast cancer patients undergoing primary surgery without preoperative treatment were collected, along with in vitro analysis to validate the potential mechanism. Results:… More >

Erdong Shen¹, Ting Pan¹, Pan Guo¹, Ke Chen¹, Rui Xu¹, Mei Yang¹, Dahe Zhan¹, Fang Fang¹, Qinghui Wu^1,*, Jianbing Hu^1,*

The International Conference on Computational & Experimental Engineering and Sciences, Vol.30, No.4, pp. 1-3, 2024, DOI:10.32604/icces.2024.012772

Abstract Objective
This study investigates the synergistic effects of a novel multifunctional nanoparticle on gastric cancer treatment through photothermal therapy, chemotherapy, and immunotherapy.

Method
Synthesize hollow mesoporous Prussian blue nanoparticles and load them with luteolin. Use exosomes to encapsulate the nanoparticles and modify the surface of the targeted peptide GX1. Detect the morphology of nanoparticles using a nanoparticle size analyzer and transmission electron microscopy. Use Coomassie Brilliant Blue to detect the effect of extracellular vesicle encapsulation. Detect the thermal conversion efficiency of nanoparticles under specific laser irradiation through infrared and ultraviolet spectroscopy, as well as the release rate… More >

WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*

Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227 - 22 May 2023

Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous… More >

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942 - 22 May 2023

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract

PARISA SHIRI AGHBASH^1,2,4, NIMA HEMMAT¹, BEHZAD BARADARAN^1,3, AHAD MOKHTARZADEH¹, VAHDAT POORTAHMASEBI^2,4, MAHIN AHANGAR OSKUEE^2,4, HOSSEIN BANNAZADEH BAGHI^1,2,4,*

Oncology Research, Vol.30, No.3, pp. 99-116, 2022, DOI:10.32604/or.2022.026776 - 12 January 2023

Abstract Infection with high-risk human papillomavirus (HPV), including HPV-16 and HPV-18, is the main cause of malignancies, such as cervical cancer. Viral oncoproteins encoded by HPV are expressed in HPV-positive cancers and associated with the early cancer stages and the transformation of normal cells. The signaling pathways involved in the transformation of normal cells to cancerous form and the subsequently expressed programmed cell death-ligand 1 (PD-L1) on the surface of the transformed cells lead to a disruption in recognition of tumor cells by the immune cell system, including T lymphocytes and dendritic cells which lead to… More > Graphic Abstract

Luca Campedel^1,†, Thomas Seisen^1,†, Justine Varinot², Géraldine Cancel-Tassin^2,3,#, Alain Ruffion⁴, Emilien Seizilles De Mazancourt⁴, Myriam Decaussin-Petrucci⁵, Grégoire Robert⁶, Nam-Son Vuong⁶, Magali Philipp⁷, Eva Compérat^2,3,#, Morgan Rouprêt^1,3,#, Olivier Cussenot^2,3,#

Canadian Journal of Urology, Vol.28, No.3, pp. 10719-10724, 2021

Abstract Introduction: Controversy regarding the prognostic and/or predictive role of PD-1 and PD-L1 expression for upper tract urothelial carcinoma (UTUC) could partly be explained by inconsistencies in the immunohistochemistry (IHC) methodology. The objective is to standardize the methodology for routine evaluation of PD-1 and PD-L1 expression in UTUC patients.
Materials and methods: Twenty-two cases treated with radical nephroureterectomy between 1996 and 2015 at 11 French hospitals were randomly selected to compare different methodologies for evaluation of PD-1 and PD-L1 expression. IHC was carried out on whole tissue sections and 0.6 mm- or 2 mm-core tissue micro-arrays (TMAs) using… More >

Jiangyong Liu^1,#,*, Mingming Gu^2,#, Yang Xue¹, Qiong Wang³, Yong Ren³, Wencai Huang^1,*

Oncologie, Vol.23, No.3, pp. 439-452, 2021, DOI:10.32604/oncologie.2021.017220 - 26 September 2021

Abstract Cavitary lung cancer is a rare type of lung cancer. Generally, the relationship between cavitary lung adenocarcinoma (LUAD) and specific immune checkpoints remains unknown. In this study, we aimed to detect the expression of programmed cell death ligand-1(PD-L1) and the density of CD8-positive (CD8⁺) tumor-infiltrating lymphocytes (TILs) to evaluate their clinicopathological significance in the case of patients with cavitary LUAD. This study included 65 patients with cavitary LUAD. Patient specimens were obtained from surgery. The expression of PD-L1 protein and CD8⁺ TIL status was detected by traditional immunohistochemistry and multiplex quantitative immunofluorescence technology. The correlation of… More >